PMV Pharmaceuticals, Inc.

NASDAQ:PMVP

Biotechnology

Healthcare
$1.22 +3.91%

+$0.04 today

Market cap
$65.06M
Beta
1.36
P/E (TTM)
-0.8
EPS (TTM)
-$1.47
52W Low $0.96High $1.88

Volume 0.43M

Average 0.38M

PMVP Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

PMV Pharmaceuticals, Inc.NASDAQ: PMVP

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of $15.3M fell 12.3% year over year, behind the +8.5% change in trailing-twelve-month research & development. Sequentially, it fell 3.4% from the prior quarter. Over 3 fiscal years it compounded at +10.6% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -12.3% toward the trailing-twelve-month pace of +8.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$15.3M-3.4% QoQ
Last fiscal yearDec 2025
$69.88M+21.8% YoY
LTMMar 2026
$67.7M+8.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.3%——
1 year+21.8%——
3-year CAGR+10.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
69.88M USD
Year-over-year change
+21.8%
4-year CAGR
+17.9%

Research & Development vs competitors

How PMVP compares with its peers on the latest reported figures

  • PMVP's LTM Mar 2026 research & development of $67.7M is the 4th highest of the 9 companies compared; the peer median is $57.69M.
  • Its year-over-year change of +8.5% is the 2nd highest of 9, against a peer median of -8.6%.
  • Over three fiscal years its annual growth of +10.6% compares with a peer median of +18.0%.
PMVP Competitors Peer median
Research & Development for PMVP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$200.25M +133.0%+35.5%78.3%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$106.27M -5.4%+24.0%1163.2%
IMUXImmunic, Inc.LTM Mar 2026$86.08M +3.9%+4.8%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$67.7M +8.5%+10.6%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$59.66M -11.8%+35.8%—
ATYRaTyr Pharma, Inc.LTM Mar 2026$55.72M +5.5%+12.0%29327.4%
BMEABiomea Fusion, Inc.LTM Mar 2026$48.2M -55.0%-0.4%—
CBUSCibus, Inc.LTM Mar 2026$41.12M -18.1%+56.4%959.3%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$23.02M -48.6%-81.3%—
Peer median (excluding PMVP) $57.69M-8.6%+18.0%1061.2%

Competitors are the stored peer set for PMVP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.28M650K1.26M1.14M0
Gross Profit(1.28M)(650K)(1.26M)(1.14M)0
Gross Margin—————
Research & Development36.19M51.67M54.63M57.38M69.88M
Selling, General & Admin20.83M24.72M24.25M26.92M16.33M
Operating Expenses57.01M76.39M78.88M84.3M86.21M
Depreciation & Amortization1.28M650K1.26M1.14M133K
EBITDA(56.54M)(72.68M)(67.7M)(73.67M)(79.78M)
EBITDA Margin—————
Operating Income(58.29M)(77.04M)(80.13M)(85.45M)(86.21M)
Operating Margin—————
Interest Income449K3.63M11.17M10.66M6.34M
Interest Expense00000
Other Income / Expenses470K3.71M11.17M10.64M6.29M
Income Before Tax(57.82M)(73.33M)(68.96M)(74.81M)(79.91M)
Pre-Tax Margin—————
Income Tax Expense23K(9K)2K(16.1M)(2.17M)
Net Income(57.85M)(73.32M)(68.96M)(58.71M)(77.74M)
Net Margin—————
EPS (Basic)(1.28)(1.61)(1.44)(1.14)(1.48)
EPS (Diluted)(1.28)(1.61)(1.44)(1.14)(1.48)
Weighted Avg Shares45.14M45.59M48.01M51.58M52.54M
Weighted Avg Shares (Diluted)45.14M45.59M48.01M51.58M52.54M

PMV Pharmaceuticals, Inc.

NASDAQ:PMVP

Intrinsic Alpha fair value

Locked

Current Price

$1.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.